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1. INTRODUCTION 
Ocular tissues contain potent mitogens that sti- 
mulate the in vitro proliferation of BEL cells [ 1,2] as 
well as cells from non-ocular tissues from different 
species [3]. These mitogens fulfilled the criteria 
proposed for the definition of a cell growth factor 
[4] and were named eye-derived growth factor 
(EDGF) [3]. Retinal EDGF, purified > lOOO-fold, 
induced maximum cell growth at doses similar to 
those used with EGF and FGF 131. Although the Mr 
estimates of EDGF differed from EGF and FGF 
[3,5], EDGF and EGF had identical isoelectric 
points at pH 4.5 2 0.5 and comparative studies of 
their biological properties on several target cells 
were similar [3]. Both factors stimulated cornea1 
endothelium ]6,7], chondrocytes [3,7] and epider- 
ma1 cells [8,9]. EDGF stimulated BEL cells to divi- 
de, but EGF did not, even though receptors for 
EGF were detected on BEL cells [3,6,10]. In con- 
trast, we found that HF cells were not stimulated by 
EDGF [9]. HF cells have EGF receptors and con- 
sistently respond to its mitogenic effect [ 11,121. We 
now extend our studies and show that HF cells also 
have receptors for EDGF and, by competition ex- 
periments, the EDGF receptors are distinct from 
those of EGF. Furthermore, to determine that the 
mitogenic activity found in our EDGF preparations 
was not due to EGF contamination, we used a ra- 
dioimmunoassay for EGF to screen our EDGF 
preparations. Mitogenic levels of EGF were not 
detected. 
2. MATERIALS AND METHODS 
2.1. Cell cultures 
HF cells were routinely grown in Dulbecco’s 
modified Eagle’s medium with 10% fetal calf 
serum [ 121. Two days prior to radioreceptor assay, 
cells were plated in 24 well culture dishes (2 
cm*/well) at 5 x lo4 cells/cm*. The medium was 
changed just before the assay and 0.45 ml fresh 
serum-free medium was placed into each well. 
2.2. Growth factor preparation 
mEGF was isolated from mouse submaxillary 
Abbreviations: BEL cells, bovine epithelial lens cells; HF, 
human foreskin tibroblasts; EGF, epidermal growth 
factor; EDGF, eye-derived growth factor; PBS, phos- 
phate-buffered saline 
glands following the procedure in [13] or obtained 
from Collaborative Research Labs. Both prepara- 
tions induced maximum stimulation of HF cells at 
10 ng/ml culture medium. EDGF was purified 
from adult bovine retina. Retina were homogenized 
in PBS and centrifuged at 20 000 x g for 30 min 
and at 100 000 X g for 16 h. Ammonium sulfate was 
added to the supernatant o bring the salt to 20%, 
and after centrifugation at 20 000 X- g for 30 min, 
protein components were further concentrated by 
bringing the salt to 60% ammonium sulphate. The 
precipitate was resuspended in 10 vol. PBS and dia- 
lysed overnight against 0.1 N acetic acid. The super- 
natant obtained after a centrifugation at 20 000. 
x g for 30 min was then dialysed against PBS. The 
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precipitations yielded a 50-fold purification of 
EDGF. Further purification, - lOOO-fold, was 
achieved by high-pressure liquid chromatography 
on silicium-grafted columns (1-125, Waters Assoc.). 
EDGF was found in the fractions eluted between 
15 000-20 000 M,. This material induced maximal 
13H]thymidine incorporation into DNA of BEL 
cells at 100 ng/ml culture medium (in preparation). 
Protein concentration was measured using bovine 
serum albumin as standard as in [ 141. 
2 3 . . “‘I-mEGF and 12jI-EDGF 
Iodination was carried out using ‘25I-Na car- 
rier-free (Amersham) and the chloramine T pro- 
cedure 1151. Specific activities of ‘251-mEGF and 
‘251-EDGF were 30-50 @i/pg and SO-100 
pCilp.g, respectively. 
2.4. Radioimmunoassay 
Radioimmunoassays were performed in 0.025 M 
sodium barbital buffer (pH 7.9); 0.1 ml rabbit anti- 
mEGF diluted 1:2000 (Collab. Res.) was added 
to various amounts of unlabeled mEGF or EDGF. 
After 2 h incubation at 37°C ‘251-mEGF was 
added to 0.22 x lo6 cpm/ml and the reaction 
mixture was centrifuged. Second antibody (goat 
antiserum against rabbit) was then added for ano- 
ther 2 h at 37°C and the immunocomplex precipi- 
tated recovered after centrifugation. 
2.4. 12’1-EDGF binding 
Increasing concentrations of ‘251-labeled EDGF 
(l- 1000 ng/ml) were added to cultures. Cells were 
incubated at 37°C for 1 h and the reaction was 
stopped by washing each dish 4 times with cold 
PBS. Cells were trypsinized (1 ml trypsin, 0.25%) 
and lysed with 1 ml lysing buffer [ 121. Radioactivity 
was measured with a Beckman Biogamma II coun- 
ter. Non-specific binding was measured by adding 
excess unlabeled EDGF (5 pg/dish) to a duplicate 
set of reaction plates at each point. 
2.5. Competitive binding studies 
Competition between ‘251-mEGF and unlabeled 
EGF or EDGF or a mixture of both was done as 
follows. To each well containing 440 ~1 culture me- 
dium, 10 ~1 ‘251-mEGF (lo6 cpm) was added and 50 
~1 of the appropriate amount of unlabeled mEGF 
or EDGF was added. 
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3. RESULTS 
3.1. Cross-immunoreactivity between EGF and 
EDGF 
Immunological cross-reactivity between EGF 
and EDGF was tested in a radioimmunoassay 
(fig.l). Large amounts of EDGF, up to 50 pg/ml, a 
500-fold greater dose than needed for maximum 
stimulation of DNA synthesis in BEL cells, showed 
no detectable cross-reactivity with EGF. Over 95% 
of the labeled EGF remained free when only 35 
ng/ml of unlabeled EGF was added. Since the limit 
of detection of EGF was -0.1 ng/ml (inducing a 
displacement of 2-3% of the 100% of the control), 
the EDGF preparations contained less than this 
amount. If EGF contamination existed in our prep- 
arations, it would be unlikely that the maximum 
stimulation of BEL cells obtained with 200 ng 
EDGF could be due to contamination by ~0.1 ng 
EGF. Maximum stimulation of HF cells was 
achieved at 10 ng EGF/ml (not shown) and min- 
imal doses of stimulation by EGF was at 0.1 ng 
EGF. 
3.2. Specific EDGF binding to HFJibroblasts 
Fig.2 shows that EDGF binds to HF cells. Maxi- 
mum binding was obtained at 750 ng EDGF/ml 
(after 60 min at 37°C). EDGF binding was enhanced 
by the addition of 10 ng EGF/ml. The shape of 
the binding curve was similar to the binding of 
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Fig. 1. Radioimmunoassay for mEGF: Precipitation of 
‘251-mEGF-anti-EGF immunocomplex after antibody 
reaction with unlabeled EGF (O-O) and with unlabeled 
EDGF (o---o). 
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Fig.2. Binding of lZ51-EDGF to human foreskin tibro- 
blasts with (0-e) or without 10 ng mEGF/ml (O-O); 
see section 3. 
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Fig.3. Radioreceptor assay for EDGF: Displacement of 
t251-EDGF binding is shown for unlabeled EDGF 
(O-O) or unlabeled EGF (O-O). 
mEGF and retinoids to target cells [ 161 and suggests 
2 types of binding sites: one type with high affinity 
and low capacity (fig2A) and another with lower 
affinity and increased capacity (lig.2B). The shape 
of the curves were identical in 5 separate expt. A 
radioreceptor assay using 1251-EDGF and cold 
EDGF was performed (tig.3); 50% competition was 
obtained at - 200 ng/ml and maximal competition 
was achieved at - 3000 ng/ml. 
3.3. mEGF radioreceptor assay and EDGF competi- 
tion 
Addition of cold mEGF or a mixture of EDGF 
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1 5 10 50 150 
EGF (ng x ml-‘) 
Fig.4. Radioreceptor assay for mEGF: Displacement of 
tZ51-mEGF binding to its receptors on human foreskin 
fibroblasts was studied with various amounts of mEGF 
alone (-A), EDGF alone (O-O) or mEGF plus 
EDGF (o---o). 
and mEGF displaced 1251-mEGF; 50% competition 
was obtained at 10 ng mEGF/ml (tig.4); EDGF 
alone did not displace bound 1251-mEGF even at 
the high dose of 1000 ng/ml (not shown). Interest- 
ingly, at smaller doses of EDGF, mEGF binding 
was enhanced - 10-208. 
4. DISCUSSION 
Our studies indicate that EDGF and mEGF are 
immunologically distinct. EDGF and mEGF may 
bind to different cell surface components and, in 
appropriate competition studies, do not compete 
for each other’s specific receptors. Furthermore, our 
EDGF preparations did not contain EGF in 
amounts currently detectable by radioimmune or 
radioreceptor assays. This point is important be- 
cause EGF has been detected in trace amounts in 
virtually all tissues tudied. It is found in the peri- 
pheral circulation ofmammals, particularlyman and 
rodents, at - l-5 ng/ml, concentrations that are 
potently mitogenic [171. mEGF has highly specific 
and reproducible effects on the acceleration of 
eyelid opening in the neonatal mouse and has spe- 
cific effects on epithelial and mesenchymal cells of 
the eye [ 131. We were concerned that the mitogenic 
activity of the eye extracts could be accounted for by 
EGF. The mitogenic activity of somatomedin B was 
found to be due to EGF contamination [18]. Our 
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results show no evidence of EGF contamination in 
our EDGF preparations and further establish 
EDGF as a unique mitogenic agent. 
Although receptors for both EDGF and EGF are 
found on a wide variety of cell types from different 
species, the presence of receptors does not appar- 
ently mean that the cells will show a mitogenic 
effect. BEL cells have receptors for both EDGF and 
EGF but only EDGF stimulated the BEL cells to 
divide in the presence of fetal calf serum. In con- 
trast, HF cells responded to EGF and not to EDGF 
[3,6,10]. Small amounts of EGF did, in fact, poten- 
tiate the total amount of EDGF binding to both 
BEL and HF cells but the enhanced EDGF binding 
did not appear to translate into an enhanced mito- 
genie effect (unpublished). Synergistic effects bet- 
ween polypeptide growth factors, phorbol esters, 
retinoids and glucocorticoids on cultured cells have 
been observed [ 19-211. Modulation of the specific 
binding of one growth factor by another may, in 
some instances, directly affect the mitogenic re- 
sponsiveness of target cells 1201. The potentiating 
effect of these factors may be related to increased 
trans-membrane movement of metabolic precur- 
sors essential for cell division and not to a direct 
mitogenic stimulation 120,221. Platelet-derived 
growth factor (PDGF) induced a transient 
down-regulation of EGF receptors and inhibited 
any further effect of EGF, suggesting some com- 
mon relationship between EDGF and EGF recep- 
tors 1231. The effect of EGF on EDGF binding is 
analogous to the glucocorticoid effect on EGF bin- 
ding 1191. It is apparent that growth factors may 
have multiple roles as conditioning agents as well as 
primary growth promoters. 
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